S&P 500   3,585.62 (-1.51%)
DOW   28,725.51 (-1.71%)
QQQ   267.26 (-1.70%)
AAPL   138.20 (-3.00%)
MSFT   232.90 (-1.94%)
META   135.68 (-0.54%)
GOOGL   95.65 (-1.82%)
AMZN   113.00 (-1.57%)
TSLA   265.25 (-1.10%)
NVDA   121.39 (-0.66%)
NIO   15.77 (+1.22%)
BABA   79.99 (+1.18%)
AMD   63.36 (-1.22%)
T   15.34 (-1.22%)
MU   50.10 (+0.18%)
CGC   2.73 (-1.80%)
F   11.20 (-2.35%)
GE   61.91 (-1.31%)
DIS   94.33 (-3.20%)
AMC   6.97 (-1.83%)
PYPL   86.07 (-2.97%)
PFE   43.76 (-0.91%)
NFLX   235.44 (-1.78%)
S&P 500   3,585.62 (-1.51%)
DOW   28,725.51 (-1.71%)
QQQ   267.26 (-1.70%)
AAPL   138.20 (-3.00%)
MSFT   232.90 (-1.94%)
META   135.68 (-0.54%)
GOOGL   95.65 (-1.82%)
AMZN   113.00 (-1.57%)
TSLA   265.25 (-1.10%)
NVDA   121.39 (-0.66%)
NIO   15.77 (+1.22%)
BABA   79.99 (+1.18%)
AMD   63.36 (-1.22%)
T   15.34 (-1.22%)
MU   50.10 (+0.18%)
CGC   2.73 (-1.80%)
F   11.20 (-2.35%)
GE   61.91 (-1.31%)
DIS   94.33 (-3.20%)
AMC   6.97 (-1.83%)
PYPL   86.07 (-2.97%)
PFE   43.76 (-0.91%)
NFLX   235.44 (-1.78%)
S&P 500   3,585.62 (-1.51%)
DOW   28,725.51 (-1.71%)
QQQ   267.26 (-1.70%)
AAPL   138.20 (-3.00%)
MSFT   232.90 (-1.94%)
META   135.68 (-0.54%)
GOOGL   95.65 (-1.82%)
AMZN   113.00 (-1.57%)
TSLA   265.25 (-1.10%)
NVDA   121.39 (-0.66%)
NIO   15.77 (+1.22%)
BABA   79.99 (+1.18%)
AMD   63.36 (-1.22%)
T   15.34 (-1.22%)
MU   50.10 (+0.18%)
CGC   2.73 (-1.80%)
F   11.20 (-2.35%)
GE   61.91 (-1.31%)
DIS   94.33 (-3.20%)
AMC   6.97 (-1.83%)
PYPL   86.07 (-2.97%)
PFE   43.76 (-0.91%)
NFLX   235.44 (-1.78%)
S&P 500   3,585.62 (-1.51%)
DOW   28,725.51 (-1.71%)
QQQ   267.26 (-1.70%)
AAPL   138.20 (-3.00%)
MSFT   232.90 (-1.94%)
META   135.68 (-0.54%)
GOOGL   95.65 (-1.82%)
AMZN   113.00 (-1.57%)
TSLA   265.25 (-1.10%)
NVDA   121.39 (-0.66%)
NIO   15.77 (+1.22%)
BABA   79.99 (+1.18%)
AMD   63.36 (-1.22%)
T   15.34 (-1.22%)
MU   50.10 (+0.18%)
CGC   2.73 (-1.80%)
F   11.20 (-2.35%)
GE   61.91 (-1.31%)
DIS   94.33 (-3.20%)
AMC   6.97 (-1.83%)
PYPL   86.07 (-2.97%)
PFE   43.76 (-0.91%)
NFLX   235.44 (-1.78%)
NASDAQ:BNGO

Bionano Genomics - BNGO Stock Forecast, Price & News

$1.83
-0.04 (-2.14%)
(As of 09/30/2022 12:00 AM ET)
Add
Compare
Today's Range
$1.83
$1.95
50-Day Range
$1.69
$3.60
52-Week Range
$1.16
$6.28
Volume
2.94 million shs
Average Volume
7.51 million shs
Market Capitalization
$530.15 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$10.33

Bionano Genomics MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
464.7% Upside
$10.33 Price Target
Short Interest
Bearish
14.15% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.83mentions of Bionano Genomics in the last 14 days
Based on 6 Articles This Week
Insider Trading
Selling Shares
$72,400 Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($0.44) to ($0.45) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.61 out of 5 stars

Medical Sector

1005th out of 1,093 stocks

Analytical Instruments Industry

26th out of 29 stocks

BNGO stock logo

About Bionano Genomics (NASDAQ:BNGO) Stock

Bionano Genomics, Inc. provides genome analysis software solutions. It offers Saphyr, a sample-to-result solution for structural variation analysis by optical genome mapping for genome analysis and understanding of genetic variation and function; Saphyr instrument, a single-molecule imager; Saphyr Chip, a consumable that packages the nanochannel arrays for DNA linearization; and Bionano Prep Kits and DNA labeling kits, which provide the reagents and protocols for extracting and labeling ultra-high molecular weight. The company also provides Saphyr and Bionano compute servers; and NxClinical which offers one system for analysis and interpretation of genomic variants from microarray and next-generation sequencing data for cytogenetics and molecular genetics. In addition, it offers testing and laboratory services comprising FirstStepDx PLUS, a chromosomal microarray for identifying an underlying genetic cause in individuals with autism spectrum disorder, developmental delay, and intellectual disability; Fragile X syndrome (FXS) testing services; NextStepDx PLUS, a exome sequencing test to identify genetic variants that are associated with disorders of childhood development; EpiPanelDx PLUS, a genetic testing panel for patients who have experienced seizures, infantile spasms, encephalopathy, or febrile seizures; PGx test, which identifies over 60 alleles in 11 genes. The company was founded in 2003 and is headquartered in San Diego, California.

Receive BNGO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Bionano Genomics and its competitors with MarketBeat's FREE daily newsletter.

BNGO Stock News Headlines

Meme-Stock Mania Is Leaving These Genomics Stocks
These 2 Penny Stocks Have Tantalizing Growth Prospects
10 Best Penny Stocks to Invest $100
See More Headlines
Receive BNGO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Bionano Genomics and its competitors with MarketBeat's FREE daily newsletter.

BNGO Company Calendar

Last Earnings
8/04/2022
Today
9/30/2022
Next Earnings (Estimated)
11/03/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Analytical instruments
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:BNGO
Fax
N/A
Employees
299
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$10.33
High Stock Price Forecast
$12.00
Low Stock Price Forecast
$7.00
Forecasted Upside/Downside
+464.7%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

Net Income
$-72,430,000.00
Net Margins
-453.68%
Pretax Margin
-478.04%

Debt

Sales & Book Value

Annual Sales
$17.98 million
Book Value
$1.17 per share

Miscellaneous

Free Float
286,221,000
Market Cap
$530.15 million
Optionable
Not Optionable
Beta
2.14

Key Executives

  • Dr. Robert Erik Holmlin M.B.A. (Age 54)
    Ph.D., Pres, CEO, Sec. & Director
    Comp: $660.84k
  • Mr. Mark Oldakowski (Age 48)
    Chief Operating Officer
    Comp: $487.73k
  • Mr. Richard Shippy (Age 52)
    Chief Bus. Officer
    Comp: $321.72k
  • Mr. Christopher P. Stewart (Age 52)
    Chief Financial Officer
  • Ms. Helene Klein
    Chief People Officer
  • Dr. Alka Chaubey FACMG (Age 49)
    Ph.D., Chief Medical Officer
  • Dr. Soheil Shams Ph.D. (Age 57)
    Chief Informatics Officer
  • Mark Adamchak
    Controller
  • Dr. Paul R. Selvin Ph.D.
    Scientific Advisor
  • Prof. Pui-Yan Kwok M.D.
    Ph.D., Scientific Advisor













BNGO Stock - Frequently Asked Questions

Should I buy or sell Bionano Genomics stock right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Bionano Genomics in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" BNGO shares.
View BNGO analyst ratings
or view top-rated stocks.

What is Bionano Genomics' stock price forecast for 2022?

3 brokerages have issued 1 year price objectives for Bionano Genomics' shares. Their BNGO share price forecasts range from $7.00 to $12.00. On average, they anticipate the company's stock price to reach $10.33 in the next year. This suggests a possible upside of 443.9% from the stock's current price.
View analysts price targets for BNGO
or view top-rated stocks among Wall Street analysts.

How have BNGO shares performed in 2022?

Bionano Genomics' stock was trading at $2.99 on January 1st, 2022. Since then, BNGO shares have decreased by 36.5% and is now trading at $1.90.
View the best growth stocks for 2022 here
.

When is Bionano Genomics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 3rd 2022.
View our BNGO earnings forecast
.

How were Bionano Genomics' earnings last quarter?

Bionano Genomics, Inc. (NASDAQ:BNGO) issued its earnings results on Thursday, August, 4th. The company reported ($0.11) earnings per share for the quarter, missing the consensus estimate of ($0.10) by $0.01. The business had revenue of $6.67 million for the quarter, compared to the consensus estimate of $6.20 million. Bionano Genomics had a negative net margin of 453.68% and a negative trailing twelve-month return on equity of 33.21%.

What guidance has Bionano Genomics issued on next quarter's earnings?

Bionano Genomics updated its FY 2022 earnings guidance on Thursday, September, 1st. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $24.00 million-$27.00 million, compared to the consensus revenue estimate of $26.20 million.

What is R. Erik Holmlin's approval rating as Bionano Genomics' CEO?

17 employees have rated Bionano Genomics Chief Executive Officer R. Erik Holmlin on Glassdoor.com. R. Erik Holmlin has an approval rating of 73% among the company's employees. 71.0% of employees surveyed would recommend working at Bionano Genomics to a friend.

What other stocks do shareholders of Bionano Genomics own?
When did Bionano Genomics IPO?

(BNGO) raised $16 million in an initial public offering (IPO) on the week of August 20th 2018. The company issued 2,500,000 shares at a price of $6.00-$7.00 per share. Roth Capital Partners and Maxim Group served as the underwriters for the IPO and LifeSci Capital was co-manager.

What is Bionano Genomics' stock symbol?

Bionano Genomics trades on the NASDAQ under the ticker symbol "BNGO."

How do I buy shares of Bionano Genomics?

Shares of BNGO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Bionano Genomics' stock price today?

One share of BNGO stock can currently be purchased for approximately $1.90.

How much money does Bionano Genomics make?

Bionano Genomics (NASDAQ:BNGO) has a market capitalization of $550.43 million and generates $17.98 million in revenue each year. The company earns $-72,430,000.00 in net income (profit) each year or ($0.37) on an earnings per share basis.

How many employees does Bionano Genomics have?

The company employs 299 workers across the globe.

How can I contact Bionano Genomics?

Bionano Genomics' mailing address is 9540 TOWNE CENTRE DRIVE SUITE 100, SAN DIEGO CA, 92121. The official website for the company is www.bionanogenomics.com. The company can be reached via phone at (858) 888-7600 or via email at arr@lifesciadvisors.com.

This page (NASDAQ:BNGO) was last updated on 9/30/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.